user

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials (vol 393, pg 143, 2019)

被引：0
|
作者：
Cahn, P.
Madero, J. S.
Arribas, J. R.
机构：
来源：
LANCET | 2019年 / 393卷 / 10167期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：132 / 132
页数：1
相关论文
共 50 条
  • [31] Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection: 3-year results from the GEMINI studies
    Cahn, Pedro
    Madero, Juan Sierra
    Arribas, Jose
    Antinori, Andrea
    Ortiz, Roberto
    Clarke, Amanda
    Hung, Chien-Ching
    Rockstroh, Juergen
    Girard, Pierre-Marie
    Sievers, Jorg
    Man, Choy
    Urbaityte, Rimgaile
    Underwood, Mark
    Pappa, Keith
    van Wyk, Jean
    Wynne, Brian
    HIV MEDICINE, 2021, 22 : 30 - 30
  • [32] Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
    Molina, Jean-Michel
    Squires, Kathleen
    Sax, Paul E.
    Cahn, Pedro
    Lombaard, Johan
    DeJesus, Edwin
    Lai, Ming-Tain
    Xu, Xia
    Rodgers, Anthony
    Lupinacci, Lisa
    Kumar, Sushma
    Sklar, Peter
    Bach-Yen Nguyen
    Hanna, George J.
    Hwang, Carey
    LANCET HIV, 2018, 5 (05): : E211 - E220
  • [33] Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection-3 year results from the GEMINI studies
    Cahn, Pedro
    Madero, Juan Sierra
    Arribas, Jose
    Antinori, Andrea
    Ortiz, Roberto
    Clarke, Amanda
    Hung, Chien-Ching
    Rockstroh, Juergen
    Girard, Pierre-Marie
    Sievers, Joerg
    Man, Choy
    Urbaityte, Rimgaile
    Underwood, Mark
    Pappa, Keith
    Smith, Kimberly
    Gartland, Martin
    Aboud, Michael
    van Wyk, Jean
    Wynne, Brian
    Bernhardt, Katharina
    INFECTION, 2021, 49 (SUPPL 1) : S12 - S13
  • [34] Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection: 3-year results from the GEMINI studies
    Cahn, P.
    Sierra-Madero, J.
    Arribas, J.
    Antinori, A.
    Ortiz, R.
    Clarke, A.
    Hung, C.
    Rockstroh, J.
    Girard, P.
    Sievers, J.
    Man, C.
    Urbaityte, R.
    Underwood, M.
    Pappa, K.
    Smith, K.
    Gartland, M.
    Aboud, M.
    van Wyk, J.
    Wynne, B.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 29 - 29
  • [35] Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
    Clotet, Bonaventura
    Feinberg, Judith
    van Lunzen, Jan
    Khuong-Josses, Marie-Aude
    Antinori, Andrea
    Dumitru, Irina
    Pokrovskiy, Vadim
    Fehr, Jan
    Ortiz, Roberto
    Saag, Michael
    Harris, Julia
    Brennan, Clare
    Fujiwara, Tamio
    Min, Sherene
    LANCET, 2014, 383 (9936): : 2222 - 2231
  • [36] Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial
    Winston, Alan
    Post, Frank A.
    DeJesus, Edwin
    Podzamczer, Daniel
    Di Perri, Giovanni
    Estrada, Vicente
    Raffi, Francois
    Ruane, Peter
    Peyrani, Paula
    Crofoot, Gordon
    Mallon, Patrick W. G.
    Castelli, Francesco
    Yan, Mingjin
    Cox, Stephanie
    Das, Moupali
    Cheng, Andrew
    Rhee, Martin S.
    LANCET HIV, 2018, 5 (04): : E162 - E171
  • [37] Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study (vol 4, pg e546, 2017)
    Orrell, C.
    Hagins, D. P.
    Belonosova, E.
    LANCET HIV, 2017, 4 (12): : E535 - E535
  • [38] Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial
    Molina, Jean-Michel
    Squires, Kathleen
    Sax, Paul E.
    Cahn, Pedro
    Lombaard, Johan
    DeJesus, Edwin
    Lai, Ming-Tain
    Rodgers, Anthony
    Lupinacci, Lisa
    Kumar, Sushma
    Sklar, Peter
    Hanna, George J.
    Hwang, Carey
    Martin, Elizabeth Anne
    Martins, Marcelo
    Cahn, Pedro E.
    Lopardo, Gustavo D.
    Porteiro, Norma
    Bloch, Mark T.
    Baker, David A.
    Roth, Norman
    Moore, Richard J.
    Finlayson, Robert J.
    McMahon, James
    Rieger, Armin
    Zoufaly, Alexander
    Hartl, Sylvia
    Zangerle, Robert
    Smaill, Fiona
    Walmsley, Sharon L.
    Conway, Brian
    Rachlis, Anita
    Smith, Graham H. R.
    Perez, Carlos
    Afani, Alejandro
    Campos Barker, Maria Isabel E.
    Euenia Chahin, Carolna
    Wolff Reyes, Marcelo
    Gerstoft, Jan
    Weis, Nina
    Laursen, Alex L.
    Molina, Jean-Michel
    Yazdanpanah, Yazdan
    Cotte, Laurent
    Raffi, Francois
    Morlat, Philippe
    Girard, Pierre-Marie
    Katlama, Christine
    Rockstroh, Juergen K.
    Arasteh, Keikawus
    LANCET HIV, 2020, 7 (01): : E16 - E26
  • [39] Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial
    Raffi, Francois
    Babiker, Abdel G.
    Richert, Laura
    Molina, Jean-Michel
    George, Elizabeth C.
    Antinori, Andrea
    Arribas, Jose R.
    Grarup, Jesper
    Hudson, Fleur
    Schwimmer, Christine
    Saillard, Juliette
    Wallet, Cedrick
    Jansson, Per O.
    Allavena, Clotilde
    Van Leeuwen, Remko
    Delfraissy, Jean-Francois
    Vella, Stefano
    Chene, Genevieve
    Pozniak, Anton
    LANCET, 2014, 384 (9958): : 1942 - 1951
  • [40] Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
    Mills, Anthony
    Arribas, Jose R.
    Andrade-Villanueva, Jaime
    DiPerri, Giovanni
    Van Lunzen, Jan
    Koenig, Ellen
    Elion, Richard
    Cavassini, Matthias
    Madruga, Jose Valdez
    Brunetta, Jason
    Shamblaw, David
    DeJesus, Edwin
    Orkin, Chloe
    Wohl, David A.
    Brar, Indira
    Stephens, Jeffrey L.
    Girard, Pierre-Marie
    Huhn, Gregory
    Plummer, Andrew
    Liu, Ya-Pei
    Cheng, Andrew K.
    McCallister, Scott
    LANCET INFECTIOUS DISEASES, 2016, 16 (01): : 43 - 52
12345